PS
VRTX icon

Principal Securities’s Vertex Pharmaceuticals VRTX Stock Holding History

Principal Securities’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.94M Buy
6,578
+259
+4% +$121K 0.04% 371
2025
Q4 		$2.86M Sell
6,319
-518
-8% -$223K 0.04% 359
2025
Q3 		$2.68M Buy
6,837
+237
+4% +$99K 0.04% 367
2025
Q2 		$2.94M Buy
6,600
+1,137
+21% +$524K 0.06% 309
2025
Q1 		$2.2M Hold
5,463
– – 0.05% 330
2024
Q4 		$2.2M Buy
5,463
+1,164
+27% +$540K 0.05% 327
2024
Q3 		$2M Buy
4,299
+226
+6% +$109K 0.05% 348
2024
Q2 		$1.91M Buy
4,073
+1,127
+38% +$489K 0.05% 312
2024
Q1 		$1.23M Buy
2,946
+582
+25% +$246K 0.04% 397
2023
Q4 		$962K Buy
+2,364
New +$873K 0.04% 422

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Principal Securities's VRTX Position: Q1 2026 in Review

Principal Securities increased its Vertex Pharmaceuticals (VRTX) stake by 4.1% in Q1 2026, buying an estimated $121K and bringing the position to 6,578 shares worth $2.94M. The position accounts for 0.04% of the portfolio, ranked #371.

Principal Securities first reported a position in VRTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $2.94M in Q2 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Principal Securities held 6,578 shares of Vertex Pharmaceuticals worth $2.94M as of Q1 2026.
  • Principal Securities bought 259 Vertex Pharmaceuticals shares in Q1 2026, an estimated $121K.
  • Vertex Pharmaceuticals made up 0.04% of Principal Securities's portfolio in Q1 2026, its #371 holding.
  • Principal Securities first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • Principal Securities's Vertex Pharmaceuticals position peaked at $2.94M in Q2 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Principal Securities's 13F filing for Q1 2026, filed 13 May 2026.